Aktis Oncology (NASDAQ:AKTS) Rating Increased to Strong-Buy at Raymond James Financial

Aktis Oncology (NASDAQ:AKTS) was upgraded by equities research analysts at Raymond James Financial to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research firms have also issued reports on AKTS. William Blair initiated coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings lowered shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, June 9th. Finally, HC Wainwright boosted their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aktis Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Aktis Oncology Trading Up 9.4%

AKTS stock opened at $22.63 on Monday. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $29.16. The company’s 50 day moving average price is $19.40.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million for the quarter. Equities research analysts anticipate that Aktis Oncology will post -1.62 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.